TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Hearing instrument feature performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative opioid use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Immediate post-operative opioid use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cervical cancer screening uptake
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Follow-up triage or treatment received
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to resolution of moderate-to-severe abdominal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: AOFAS American orthopedic foot and ankle score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Circular TUG (cTUG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects who receive minimum dose of ABA
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Soft contact lens movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Soft contact lens horizontal lag
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Soft contact lens tightness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic performance for HCC detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain score at 120 minutes post-intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in hematological parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of treatment related adverse events (TRAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: End Stage Renal Disease Adherence Questionnaire (ESRD-AQ) scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Differentiation of MG-patients from non-MG participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of spinal cord injuries detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of active lesions detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diagnostic confidence of radiologists
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: in vitro metabolism of flavan-3-ols
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composition of the gut microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in words-correct scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in phonemes-correct scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in consonant-identification scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cramping Pain Following Hysteroscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Pain Following Hysteroscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in heavy drinking days
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: tissue oxygenation indicative for flap failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of overall errors in vaccination and immunization processes
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total duration of antibiotic therapy (in days)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Feasibility of cooperative gameplay
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Ability to play the game
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Subjects Experiencing Dose Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: MPR
Endpoint domain: Resource use
Primary endpoint: Change in Weekly Itch Severity Score (ISS7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analog scale measurement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Screening Uptake for Hepatitis C Virus (HCV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Screening Uptake for Colorectal Cancer (CRC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Postprandial plasma gut hormone response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Physiological effects of COVID-19 vaccines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective side effects of COVID-19 vaccines
Endpoint domain: Adverse events/effects
Primary endpoint: Psychological stress effects of COVID-19 vaccines
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in MG-ADL total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long term effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cold vapor exposure effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic performance of VAN for predicting ELVO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic performance of VES for predicting ELVO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic performance of LARIO for predicting ELVO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proliferation of Healthy Primary Human Fibroblasts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Matrix Formation by Healthy Primary Human Fibroblasts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Release of Pro-inflammatory Mediators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Drug plasma steady state concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vitamin B12 Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 25 OH Vitamin D Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: self-reported severity of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depressive Outcomes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in Fall Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Cardiovascular Risk and Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in Nerve Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: BIRADS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with markers of chronic kidney disease (CKD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Positive Inducible T-cell Co-Stimulator (ICOS) Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Positive New York Esophageal Squamous Cell Carcinoma 1 (NY-ESO-1)/Cancer Testis Antigen 2 (LAGE-1a) Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Positive Programmed Death Protein 1 Ligand (PD-L1) Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Positive result of acute SARS-CoV-2 infection
Endpoint domain: Mortality/survival
Primary endpoint: Positive result of Severe COVID-19
Endpoint domain: Mortality/survival
Primary endpoint: TAC in tears
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AA in tears
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ROS in tears
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral functioning in Asphyxiated Newborns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Breathing patterns in Asphyxiated Newborns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in olfactory evoked potentials (EOPs) in Asphyxiated Newborns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: R-wave amplitude of LBB EGM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Neuron-specific enolase (NSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC over 24H of JLP-1901
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of JLP-1901
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Structural damage of the manubriosternal joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Clinically Significant Hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Adverse Events assessed by CTCAE V5.0
Endpoint domain: Adverse events/effects
Primary endpoint: Maternal Care Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fatigue Intensity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: 1-year GVHD-free relapse-free survival (GRFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: Recruitment Time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: No Evidence of Disease Rate (NED Rate)
Endpoint domain: Mortality/survival
Primary endpoint: Patient Health Questionnaire 9-item (PHQ-9) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient-reported Pain Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-reported Anxiety Level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: knowledge score on home blood pressure monitoring
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change of pain score during cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in neurotransmitter balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mental Wellbeing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of participants with immediate adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients achieving a score of 0 or 1 on the Investigator's Global Assessment scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Motor Retention Magnitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor Learning Magnitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Digit Span Backward Test
Endpoint domain: Cognitive functioning
Primary endpoint: Digit Span Forward Test
Endpoint domain: Cognitive functioning
Primary endpoint: Incidence, frequency, and severity of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: NIH Toolbox v3
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: restoring the accurate position of eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: motility of eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: volume of orbit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total exposure level of 0.3 micron particles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic Pancreatitis-Specific Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Feasibility of Micro-Longitudinal Daily Pain Assessment
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Area under the ROC curve of total cfDNA percent change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Attention Network Task (ANT)/Attentional Control Efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Acute Fear Response (Fear Load and Fear Inhibition)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Self-Reported Attentional Control (Attentional Control Scale)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: 35m sprint time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agility test time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reaction test time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatitis D Virus (HDV) RNA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Salivary diurnal cortisol pattern change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Salivary C-reactive protein change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quality of life (visual analogue) change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Couples Satisfaction Inventory-32
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Scores on the Montreal Cognitive Assessment (MoCA) for dementia risk
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Blood levels of amyloid beta (Aβ40/Aβ42 ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: CESD-R Score Change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PHQ-9 Score Change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PSWQ Score Change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: SWLS Score Change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: PANAS Score Change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: STAI Score Change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: R-UCLA Score Change
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in acute postoperative pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity-specific Balance Confidence (ABC) scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Multisensory temporal processing performance change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postural control and gait performance change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain GABA level change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RDW to platelet ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of subjects correctly repositioned from the prone to recovery position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Need for further management
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of clinical hernia recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Antibiotics prescribed at index consultation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Hospital Anxiety and Depression Scale-Anxiety (HADS-A) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Numerical Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Brain blood flow from Arterial spin labeling magnetic resonance imaging (ASL-MRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in cognitive performance, emotions, and motor function based on NIH toolbox
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in executive function using the Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of Patients Free from Nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Complications at 3 months follow-up
Endpoint domain: Adverse events/effects
Primary endpoint: Patient-rated outcome at 12 months follow-up
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Average Daily VAS Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receipt of Cervical Cancer Screening
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of participants completing 13C pyruvate MR imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in knowledge, attitudes, risk perception, and intention/stage of readiness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Completion of a healthcare visit for lung cancer screening
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Completion of referral to smoking cessation treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Biochemically confirmed 7-day point-prevalence cigarette abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported 7-day point-prevalence cigarette abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of participants with 8-week sustained unresponsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: first desire to void
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: first sensation of bladder filling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: electrocorticographic recordings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage reduction in intraocular pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of medical devices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Osteocalcin serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Vitamin K serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Leptin serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tumour Necrosis Factor alpha serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Interleukin-1 Beta serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Interleukin-6 serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: urea nitrogen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in blood vessel dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Bone markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Post-op opioid usage
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Intensity of pain during and after open muscle biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to intervention for an arterial event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mortality attributable to an arterial event
Endpoint domain: Mortality/survival
Primary endpoint: Maximum Observed Analyte Concentration (Cmax) of Darunavir (DRV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Analyte Concentration-time Curve from time Zero to Last Quantifiable time (AUC[0-last]) of DRV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Analyte Concentration-time Curve from Time Zero to Infinite Time (AUC[0-infinity]) of DRV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degree of gastric mucosal visualization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Global cognitive performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time from study entry to virologic failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from study entry to regimen completion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Digestive health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes